IMPACT aimed to investigate how the virus affects the immune system and how people with risks for blood cancer may respond to COVID-19 and its emerging vaccines.
The IMPACT study is an affiliate study of the PROMISE and PCROWD Studies. We analyze blood samples for up to one year to learn how COVID-19 exposure affects the immune system. All participants enrolled in IMPACT will receive a free antibody test to determine if they have been exposed to the virus that causes COVID-19.
The IMPACT Study is now closed and in its follow-up stage. If you are eligible, here are two affiliate studies you can join:
Already enrolled? PROMISE Dashboard Login / PCROWD Dashboard Login
Not enrolled? The PCROWD Study is welcoming new participants. The PROMISE Study has met accrual goals and is no longer enrolling new participants for screenings.
The PROMISE Study screened healthy people with risks for multiple myeloma but who did not have the early warning signs (called precursor conditions.). This study has met its accrual goals and is no longer enrolling new participants for screenings.
Join the PCROWD Study
For anyone, age 18+, who has been diagnosed with a precursor condition for multiple myeloma.
​
​
ABOUT THIS STUDY
-
We study how the immune system responds to COVID-19 and the long-term impact of the virus in patients with precursor conditions and healthy individuals. The goals of IMPACT are:
-
To compare COVID-19 antibody levels and immune cell changes in patients with precursor conditions to those without precursor conditions.
-
To identify the people most at risk for long-term symptoms and immune complications after infection to COVID-19.
THE IMPORTANCE
The coronavirus disease, called COVID-19, continues to have a serious impact on millions of people, including people with or at risk for cancer. It is important to learn how COVID-19 will impact people with risks for blood cancer.
​
We Seek to Learn Answers to Questions Like These:
-
Do people who have risks for blood cancer also have greater risks for COVID-19?
-
If so, is there a COVID-19 treatment that would help people with cancer risks to protect their long-term health?
-
Who is most at risk for long-term symptoms and immune complications after infection with COVID-19?
-
Will precursor conditions make future COVID-19 vaccines more or less effective?
-
Do precursor patients who have recovered from COVID-19 have COVID-19 antibodies?
-
Are these patients who have recovered from COVID-19 protected from re-infection? If so, for how long?
​​